Biotech

Kineta to Receive $5 Million Milestone Payment from Merck

Discovery stage milestone triggered by validating an undisclosed target for amyotrophic lateral sclerosis (ALS) SEATTLE, June 29, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune [...]

Kineta to Receive $5 Million Milestone Payment from Merck2023-06-29T14:35:16+00:00

Kineta Set to Join Russell Microcap® Index

SEATTLE, May 24, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company is set to join the Russell Microcap® Index [...]

Kineta Set to Join Russell Microcap® Index2023-05-25T18:11:02+00:00

Surgeon General Issues New Advisory About Effects Social Media Use Has on Youth Mental Health

Surgeon General Dr. Vivek Murthy Urges Action to Ensure Social Media Environments are Healthy and Safe, as Previously-Advised National Youth Mental Health Crisis Continues Today, United States Surgeon General Dr. Vivek Murthy released a new Surgeon General’s Advisory on Social [...]

Surgeon General Issues New Advisory About Effects Social Media Use Has on Youth Mental Health2023-05-25T18:09:35+00:00

Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

SEATTLE, April 24, 2023 — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has closed its previously announced [...]

Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules2023-04-26T16:06:35+00:00

Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors

Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors: SEATTLE, April 12, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address [...]

Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors2023-04-17T18:07:29+00:00

Kineta Completes Reverse Merger with Yumanity Therapeutics

Shares of Kineta to commence trading on Nasdaq under new ticker symbol “KA” on December 19, 2022 Seattle, WA — (December 19, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address [...]

Kineta Completes Reverse Merger with Yumanity Therapeutics2023-04-17T18:07:29+00:00
Go to Top